OverviewSuggest Edit
Eutilex ((주)유틸렉스) is a biotech company developing anti-tumor T-cell therapy. Additionally, it offers antibody therapeutics based on its proprietary immunotherapy technology.
| Type | Public | |
| Founded | 2015 | |
| HQ | KR | Map |
| Website | eutilex.com |
Key People/Management at Eutilex
Byoung S. Kwon
CEO
Soo Young Choi
COO
Edwin E. Kwon
CFO
Heui Choe
CCO
Jeonghoon Han
CBO
Young Ho Kim
CDO
Eutilex Financials and Metrics
Eutilex Revenue
Market capitalization (17-Sept-2021) | 204.9b |
Closing stock price (17-Sept-2021) | 28.1k |
Eutilex's current market capitalization is ₩204.9 b.
Eutilex Cybersecurity Score
Eutilex Online and Social Media Presence
Eutilex's Trends
Eutilex News and Updates
January 27, 2021
Samsung Biologics, National OncoVenture, and Eutilex Obtain IND Approval from FDA
INCHEON, South Korea, Jan. 26, 2021 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) announced another successful Investigational New Drug (IND) clearance from the FDA for its client to begin clinical trials on a cancer immunotherapy, furthering the company's track record as a premiere...
Eutilex Frequently Asked Questions
When was Eutilex founded?
Eutilex was founded in 2015.
Who are Eutilex key executives?
Eutilex's key executives are Byoung S. Kwon, Soo Young Choi and Edwin E. Kwon.
How many employees does Eutilex have?
Eutilex has 108 employees.
Who are Eutilex competitors?
Competitors of Eutilex include Sensei Biotherapeutics, Speratum and Notch Therapeutics.
Where are Eutilex offices?
Eutilex has an office in.
How many offices does Eutilex have?
Eutilex has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies